28 results on '"Ruxrungtham Kiat"'
Search Results
2. Faculty Opinions recommendation of Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
3. Faculty Opinions recommendation of Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.
4. Faculty Opinions recommendation of A mechanistic theory to explain the efficacy of antiretroviral therapy.
5. Faculty Opinions recommendation of Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
6. Faculty Opinions recommendation of High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.
7. Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
8. Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
9. Faculty Opinions recommendation of The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
10. Faculty Opinions recommendation of Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
11. Faculty Opinions recommendation of Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
12. Faculty Opinions recommendation of Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.
13. Faculty Opinions recommendation of Timing of initiation of antiretroviral drugs during tuberculosis therapy.
14. Faculty Opinions recommendation of [CONFERENCE POSTER]: Hair as a biological marker of daily oral pre-exposure prophylaxis (PrEP) adherence and tenofovir/emtricitabine (TFV/FTC) exposure in the Global iPrEx Study.
15. Faculty Opinions recommendation of Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
16. Faculty Opinions recommendation of Lower mortality and earlier start of combination antiretroviral therapy in patients tested repeatedly for HIV than in those with a positive first test.
17. Faculty Opinions recommendation of Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
18. Faculty Opinions recommendation of Antiretroviral therapies in women after single-dose nevirapine exposure.
19. Faculty Opinions recommendation of Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
20. Faculty Opinions recommendation of Effect of early versus deferred antiretroviral therapy for HIV on survival.
21. Faculty Opinions recommendation of Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
22. Faculty Opinions recommendation of Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.
23. Faculty Opinions recommendation of HLA-B*5701 screening for hypersensitivity to abacavir.
24. Faculty Opinions recommendation of Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
25. Faculty Opinions recommendation of Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
26. Faculty Opinions recommendation of Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
27. Faculty Opinions recommendation of Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection.
28. Faculty Opinions recommendation of Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.